We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Cyclophosphamide-Prednisone Therapy of Lethal Midline Granuloma

Ezra M. Greenspan, MD
JAMA. 1965;193(1):74-76. doi:10.1001/jama.1965.03090010080031.
Text Size: A A A
Published online


LETHAL MALIGNANT midline granuloma is a relentless, destructive disorder of the facial tissues and other structures. It usually takes a progressive downhill course, lasting one to three years after the onset.1 Less than 150 cases of this rare disease of unknown etiology have been reported since McBride's first description2 in 1897. A close relationship has been postulated between lethal midline granuloma and Wegener's granulomatosis,3 which are both considered to be variants of periarteritis nodosa or other collagen-vascular diseases. A substantial number of patients with midline granuloma experience involvement of the lungs and other distant sites. Such involvements culminate in a terminal clinical state similar to that produced by progressive Wegener's granulomatosis.

Therapy of midline granuloma has been unsatisfactory despite transient response to steroids and temporary healing of individual lesions after x-radiation therapy.4 Long-term regression of progressive midline lethal granuloma by any systemic therapy has not yet


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.